Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Payables (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Payables for 9 consecutive years, with $28.3 million as the latest value for Q4 2025.

  • Quarterly Payables rose 1650.4% to $28.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.3 million through Dec 2025, up 1650.4% year-over-year, with the annual reading at $28.3 million for FY2025, 1650.4% up from the prior year.
  • Payables hit $28.3 million in Q4 2025 for Protagonist Therapeutics, up from $22.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $37.7 million in Q4 2021 to a low of $706000.0 in Q3 2021.
  • Historically, Payables has averaged $13.7 million across 5 years, with a median of $13.5 million in 2024.
  • Biggest five-year swings in Payables: plummeted 96.91% in 2023 and later surged 1650.4% in 2025.
  • Year by year, Payables stood at $37.7 million in 2021, then tumbled by 33.83% to $25.0 million in 2022, then tumbled by 96.91% to $772000.0 in 2023, then soared by 109.2% to $1.6 million in 2024, then soared by 1650.4% to $28.3 million in 2025.
  • Business Quant data shows Payables for PTGX at $28.3 million in Q4 2025, $22.9 million in Q3 2025, and $3.2 million in Q2 2025.